$5.22
0[0.00%]
At close: Apr 25
$5.22
0[0.00%]
PreMarket: 7:05PM EDT
Editas Medicine
(NASDAQ:EDIT)Latest News for Editas Medicine Stock (NASDAQ:EDIT)
Editas Medicine Stock (NASDAQ: EDIT)
Categories: All
Monday, April 22, 2024
Thursday, February 29, 2024
- The Latest Analyst Ratings For Editas MedicineBenzinga Insights - Feb 29, 2024, 12:00PM
- Citigroup Maintains Buy on Editas Medicine, Raises Price Target to $16Benzinga Newsdesk - Feb 29, 2024, 11:57AM
- Barclays Maintains Equal-Weight on Editas Medicine, Raises Price Target to $11Benzinga Newsdesk - Feb 29, 2024, 8:44AM
Wednesday, February 28, 2024
- Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Feb 28, 2024, 2:02PM
- Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Feb 28, 2024, 11:37AM
- Editas Medicine shares ar trading higher after the company reported better-than-expected Q4 financial results.Benzinga Newsdesk - Feb 28, 2024, 9:19AM
- Editas Medicine Q4 EPS $(0.23) Beats $(0.54) Estimate, Collaboration and R&D Revenue $60.05M Beat $7.94M Estimate. Cash And Equivalents $427.1MBenzinga Newsdesk - Feb 28, 2024, 7:02AM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Monday, January 08, 2024
Wednesday, December 13, 2023
Tuesday, December 12, 2023
Monday, December 11, 2023
Friday, November 03, 2023
- Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Nov 3, 2023, 1:26PM
- Editas Medicine shares are trading higher after the company reported Q3 financial results.Benzinga Newsdesk - Nov 3, 2023, 11:40AM
- Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On FridayLisa Levin - Nov 3, 2023, 11:30AM
- Earnings Scheduled For November 3, 2023Benzinga Insights - Nov 3, 2023, 7:12AM
- Editas Medicine's Cash, Cash Equivalents, And Marketable Securities As Of September 30, 2023, Were $446.4M, Expected To Provide A Cash Runway Into Q3 Of 2025Benzinga Newsdesk - Nov 3, 2023, 7:04AM
- Editas Medicine Q3 EPS $(0.55) Beats $(0.57) Estimate, Sales $5.34M Beat $3.42M EstimateBenzinga Newsdesk - Nov 3, 2023, 7:02AM
Thursday, November 02, 2023
Tuesday, October 24, 2023
Wednesday, October 18, 2023
Tuesday, October 17, 2023
- Editas Medicine Has To Navigate Sickle Cell Therapy Competition: AnalystVandana Singh - Oct 17, 2023, 2:35PM
- Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023Benzinga Insights - Oct 17, 2023, 11:00AM
- Cantor Fitzgerald Downgrades Editas Medicine to NeutralBenzinga Newsdesk - Oct 17, 2023, 9:17AM
- NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionLisa Levin - Oct 17, 2023, 6:25AM
Monday, October 16, 2023
Friday, September 29, 2023
- Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Sep 29, 2023, 2:09PM
- Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades StockVandana Singh - Sep 29, 2023, 1:40PM
- Expert Ratings for Editas MedicineBenzinga Insights - Sep 29, 2023, 11:00AM
- Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023Benzinga Insights - Sep 29, 2023, 11:00AM
- Editas Medicine shares are trading higher after Stifel upgraded the stock from Hold to Buy and raised its price target from $9 to $17.Benzinga Newsdesk - Sep 29, 2023, 9:03AM
- Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For FridayLisa Levin - Sep 29, 2023, 8:03AM
- Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market SessionLisa Levin - Sep 29, 2023, 5:59AM
- Stifel Upgrades Editas Medicine to Buy, Raises Price Target to $17Benzinga Newsdesk - Sep 29, 2023, 4:45AM
Monday, September 25, 2023
Wednesday, September 13, 2023
Tuesday, August 29, 2023
Thursday, August 03, 2023
- Expert Ratings for Editas MedicineBenzinga Insights - Aug 3, 2023, 8:00AM
- Oppenheimer Reiterates Perform on Editas Medicine, Maintains $12 Price TargetBenzinga Newsdesk - Aug 3, 2023, 7:46AM
- Chardan Capital Maintains Buy on Editas Medicine, Lowers Price Target to $19Benzinga Newsdesk - Aug 3, 2023, 4:36AM